Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Assets Average (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Assets Average for 10 consecutive years, with $147.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average rose 637.1% to $147.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $147.9 million, a 637.1% increase, with the full-year FY2023 number at $48.6 million, down 33.55% from a year prior.
  • Assets Average was $147.9 million for Q3 2025 at Crescent Biopharma, up from $81.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $147.9 million in Q3 2025 to a low of $10.8 million in Q1 2025.
  • A 5-year average of $73.7 million and a median of $62.9 million in 2022 define the central range for Assets Average.
  • Biggest YoY gain for Assets Average was 637.1% in 2025; the steepest drop was 72.72% in 2025.
  • Crescent Biopharma's Assets Average stood at $101.1 million in 2021, then plummeted by 46.72% to $53.9 million in 2022, then decreased by 8.59% to $49.3 million in 2023, then crashed by 59.28% to $20.1 million in 2024, then soared by 637.1% to $147.9 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Assets Average are $147.9 million (Q3 2025), $81.7 million (Q2 2025), and $10.8 million (Q1 2025).